BCTX MEXC RealStocks
Own real BCTX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 18:57:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Briacell Therapeutics Corp. (BCTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.49, with a market capitalization of $32.22M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.60 to $13.09. This page covers its latest market performance, valuation, price trends and company information.
$32.22M | |
$3.59 | |
$3.80 | |
$3.48 | |
$3.59 | |
40.76K | |
262.50K | |
-- | |
$13.09 | |
$2.60 | |
-- | |
-- |
Briacell Therapeutics Corp. (BCTX) is currently trading at $3.49 as of 2026-11-12 18:51:00, down 3.06% ($0.11) from the previous close of $3.59
During today's regular trading session, BCTX has traded between $3.48 and $3.80, with a trading volume of 40.76K shares. The current price is near the lower end of today's range.
Over the past seven days, Briacell Therapeutics Corp. (BCTX) moved from $3.01 to $3.49, representing a gain of 15.91% ($0.48).
The stock traded between $2.98 and $4.08 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 76.93 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 8.5%
BCTX is currently trading at $3.49, placing it 8.5% of the way from its 52-week low of $2.60 to its 52-week high of $13.09. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 31 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Briacell Therapeutics Corp.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Briacell Therapeutics Corp. (BCTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to BCTX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between BCTX shares and USD.
BCTX Shares to USD
1.00 BCTX shares = 3.489 USD
Calculations are estimates based on the latest available price and are for reference only.